Stanford built a drug company staffed by 37,000 AI agents

Stanford researchers built a virtual biotech company with more than 37,000 AI agents organized like a real firm, Labcritics reports on a Science paper. A chief-scientist agent delegates to specialists that analyzed nearly 56,000 clinical trials in under a week. It found drugs aimed at cell-type-specific genes were 40% more likely to clear Phase I and 48% more likely to reach market.